Drug Utilization Review (DUR) Board Meeting Summary - January 25, 2007

Board Meeting of January 25, 2007

Items for discussion included the Joint Application Review (JAR) sessions in preparation for the fiscal agent reprocurement, data extracts from the annual ProDUR report, the new official NYS forge-proof prescription blanks, and 'Plan B', the emergency contraceptive drug, as an over-the-counter (OTC) item. The Drug Utilization Review Board (DURB) considered a report on third generation cephalosporins and the utilization of Elidel and Protopic without a diagnosis of atopic dermatitis. The DUR Board discussed a Memorandum of Understanding with University of Massachusetts Medical School (UMMS) and the DOH process of hiring new Department of Health staff dedicated to the DUR program, as well as an update on the proposed transition of DUR from the Office of the Medicaid Inspector General to the Office of Health Insurance Programs.

The DURB was advised of the Governor's Executive Order on public meetings access which requires that DUR Board meetings must be available as video/web casts commencing July 2007. The RetroDUR focus on the ACE/ARB drugs for diabetic Medicaid recipients was discussed and the Board requested a summary by HID of the provider response rate for alert letters for the March 2007 DUR Board meeting.

"Medicaid Update" Article:

A January 2007 "Medicaid Update" article on the use of hydroxyurea in sickle cell disease written by the DUR Board was approved and published.

Meeting Summary Posted 5/19/09